Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Polyrizon Ltd. - Ordinary Shares (NQ:PLRZ)

0.7396 +0.7362 (+21652.94%)
Streaming Delayed Price Updated: 1:52 PM EDT, May 27, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Polyrizon Ltd. - Ordinary Shares

Polyrizon Announces Receipt of Nasdaq Delisting Notice
From Polyrizon Ltd.
Via GlobeNewswire
Polyrizon Emerges with Positive Preclinical Data on Nasal Protection Platform
From Polyrizon Ltd.
Via GlobeNewswire
Polyrizon Targets $3.15B Epilepsy Market with Preclinical Studies for Innovative Rescue Treatment
From Polyrizon Ltd.
Via GlobeNewswire
Polyrizon Reports Successful Safety Study of a Formulation of PL-14 Allergy Blocker in Human Nasal Tissue Model
From Polyrizon Ltd.
Via GlobeNewswire
Polyrizon Receives Nasdaq Notification Regarding Minimum Bid Requirements
From Polyrizon Ltd.
Via GlobeNewswire
BioMedNewsBreaks — Polyrizon Ltd. (NASDAQ: PLRZ) Secures $17M in Private Placement
Via Investor Brand Network
Polyrizon Engages Leading Branding Firm for Strategic Brand Development
From Polyrizon Ltd.
Via GlobeNewswire
Polyrizon Ltd. Announces Closing of $17.0 Million Private Placement
From Polyrizon Ltd.
Via GlobeNewswire
Polyrizon Ltd. Announces $17.0 Million Private Placement
From Polyrizon Ltd.
Via GlobeNewswire
Polyrizon Structures Clinical Strategy for its Allergy Blocker Ahead of FDA Pre-Submission Meeting
From Polyrizon Ltd.
Via GlobeNewswire
Polyrizon Expands Drug Delivery Innovation with Preclinical Studies for Epilepsy Rescue Treatment
From Polyrizon Ltd.
Via GlobeNewswire
Clearmind to Evaluate Intranasal Delivery of Its Psychedelic Drug Combination
From Clearmind Medicine Inc.
Via GlobeNewswire
Polyrizon Signs Non– Binding LOI to Expand its Innovative Intranasal Drug Delivery Platform for Psychedelic-Based Treatments
From Polyrizon Ltd.
Via GlobeNewswire
Polyrizon Launches Preclinical Studies for Intranasal Naloxone to Combat Opioid Overdose Using Cutting-Edge Platform
From Polyrizon Ltd.
Via GlobeNewswire
Polyrizon Ltd. Files Annual Report on Form 20-F for the Fiscal Year Ended December 31, 2024
From Polyrizon Ltd.
Via GlobeNewswire
Polyrizon Initiates Preclinical Studies for Intranasal Naloxone Targeting Opioid Overdose Based on Its Innovative T&T Platform
From Polyrizon Ltd.
Via GlobeNewswire
Polyrizon Announces Filing of Divisional Patent Application for Its Innovative Trap & Target™ (T&T) Intranasal Drug Delivery Platform
From Polyrizon Ltd.
Via GlobeNewswire
Polyrizon Commences GMP Manufacturing Preliminary Process for its PL-14 Allergy Blocker in Preparation for Planned 2025 Clinical Trial
From Polyrizon Ltd.
Via GlobeNewswire
Polyrizon Announces Publication of U.S. National Patent Application for Its Innovative Hydrogel Nasal Technologies
From Polyrizon Ltd.
Via GlobeNewswire
Polyrizon Appoints Dr. Michal Meir as Senior Director of Regulatory and Clinical Affairs
From Polyrizon Ltd.
Via GlobeNewswire
Polyrizon's Moving Forward with Expected 2025 Clinical Trial - Entered Manufacturing Agreement for its PL-14 Allergy Blocker
From Polyrizon Ltd.
Via GlobeNewswire
Polyrizon Announces Appointment of VP of Regulatory Affairs and Quality Assurance
From Polyrizon Ltd.
Via GlobeNewswire
Polyrizon Enters into GMP Manufacturing Agreement for CTM Supply of its PL-14 Allergy Blocker in Preparation for Planned 2025 Clinical Trial
From Polyrizon Ltd.
Via GlobeNewswire
BioMedNewsBreaks — Polyrizon Ltd. (NASDAQ: PLRZ) Secures $4.2M in Initial Public Offering
Via Investor Brand Network
Aegis Capital Corp. Acted as Sole Bookrunner on a $4.2 Million (IPO) Initial Public Offering for Polyrizon Ltd. (NASDAQ: PLRZ)
Via ACCESSWIRE
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.